0.4445

2.87% -0.0086

Neurosense Therapeutics Ltd (NRSN)

Overview News Price History Discussions Forecast

Neurosense Therapeutics Ltd stock is traded at $0.4445, with a volume of 355.23K. It is down -2.87% in the last 24 hours and down -35.66% over the past month. NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Previous Close:

$0.4531

Open:

$0.483

24h Volume:

355.23K

Relative Volume:

1.86

Market Cap:

$16.71M

Revenue:

Net Income/Loss:

$-10.21M

P/E Ratio:

-0.7609

EPS:

-0.5842

Net Cash Flow:

1W Performance:

-9.11%

1M Performance:

-35.66%

6M Performance:

-55.99%

1Y Performance:

-63.02%

1-Day Range:

$0.4339

$0.51

1-Week Range:

$0.4321

$0.5101

52-Week Range:

$0.393

$1.98

Neurosense Therapeutics Ltd Stock (NRSN) Company Profile

Name

Neurosense Therapeutics Ltd

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

Address

Employee

Twitter

Next Earnings Date

2026-06-30

Latest SEC Filings

NRSN's Discussions on Twitter

Compare NRSN vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NRSN Neurosense Therapeutics Ltd	0.4424	17.11M	0	-10.21M	0	-0.5842
VRTX Vertex Pharmaceuticals Inc	515.27	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.54	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.75	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.57	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.12	39.31B	5.76B	514.49M	1.10B	4.4813

Neurosense Therapeutics Ltd Stock (NRSN) Latest News

Aug 14, 2026

Neurosense Therapeutics Stock Price Forecast. Should You Buy NRSN? - StockInvest.us

Aug 14, 2026

Aug 13, 2026

Amyotrophic Lateral Sclerosis Pipeline Shows Strong Momentum as 80+ Pharma Companies in the Race | DelveInsight - openPR.com

Aug 13, 2026

NeuroSense CEO Details Phase 3 ALS Trial Plans, Canada Filing and Nasdaq Compliance Efforts - TipRanks

Aug 13, 2026

NeuroSense Issues CEO Letter to Shareholders - PR Newswire

Aug 13, 2026

Aug 12, 2026

NeuroSense Therapeutics (NRSN) Slips to $0.47 as Bulls Defend Key Support FloorNHNL Ratio - dars.gov.et

Aug 12, 2026

Aug 11, 2026

Global Neurodegenerative Disease Market is Expected to - GlobeNewswire

Aug 11, 2026

Aug 06, 2026

NeuroSense Advances PrimeC Toward December 2026 Health Canada Filing After Completing Pre-NDS Process - TipRanks

Aug 06, 2026

Health Canada review path for PrimeC: NeuroSense (NASDAQ: NRSN) - Stock Titan

Aug 06, 2026

NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada - Nasdaq

Aug 06, 2026

Aug 03, 2026

NeuroSense Therapeutics Ltd. SEC Filing (Aug 3, 2026) - Stock Titan

Aug 03, 2026

Jul 31, 2026

NeuroSense Therapeutics Calls August 26 Shareholder Vote on Wide-Range Reverse Share Split - TipRanks

Jul 31, 2026

NeuroSense Therapeutics (NRSN) seeks reverse split amid Nasdaq compliance push - Stock Titan

Jul 31, 2026

Jul 30, 2026

NeuroSense Therapeutics (NRSN) sets $150M shelf and $3.8M ATM share plan - Stock Titan

Jul 30, 2026

Jul 28, 2026

Neurosense Therapeutics is a buy, this analyst says - Cantech Letter

Jul 28, 2026

Neurosense Therapeutics Ltd expected to post breakeven results a shareEarnings Preview - TradingView

Jul 28, 2026

Jul 27, 2026